#China #Hong Kong #Medical Device #LuX-Valve Plus #Jenscare Scientific

LuX-Valve Plus Now Approved for Hong Kong-Macao Region

In a significant milestone for the medical device industry, Jenscare Scientific Co., Ltd. has announced that its innovative product, the LuX-Valve Plus, has been officially approved for inclusion in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect. This approval enables commercial clinical application within designated healthcare institutions throughout the Greater Bay Area (GBA) of mainland China.

The Hong Kong-Macao Medicine and Equipment Connect is a progressive medical innovation policy aimed at enhancing healthcare delivery in the Guangdong-Hong Kong-Macao region. This policy allows urgently required medicines and medical devices, previously used in public hospitals across Hong Kong and Macao, to be utilized in mainland healthcare facilities after obtaining the necessary approvals. This move is crucial for meeting the urgent clinical needs of patients facing serious health challenges.

The LuX-Valve Plus is a transjugular tricuspid valve replacement system meticulously developed for patients suffering from severe tricuspid regurgitation (TR), particularly those who are at high surgical risk. TR poses significant clinical dilemmas, especially in patients with complex anatomical structures or severely dilated tricuspid annular regions, where traditional surgical options may not be safe or feasible.

What sets the LuX-Valve Plus apart is its cutting-edge design, which features a globally innovative mechanism that incorporates ventricular-septum anchoring alongside a self-adaptive anti-leak ring. This transcatheter system is accessible in seven varying sizes (40mm to 70mm), thus catering to a diverse range of anatomical challenges commonly encountered in TR patients.

The LuX-Valve Plus has already been successfully implanted in numerous patients across several major markets, including regions such as North America, Europe, and the Middle East. According to follow-up data, these implants have shown promising safety and efficacy profiles, earning the product widespread recognition in the international market.

With this new approval, Jenscare is primed to leverage the opportunity to promote the LuX-Valve Plus extensively. The company aims to accelerate its market penetration and fulfill the significant unmet clinical needs of TR patients, thereby contributing to enhanced patient outcomes in the region. Jenscare's commitment to resolving these challenges aligns with its long-term vision of sustainable growth and revenue generation through global expansion.

As Jenscare actively engages in the commercialization of the LuX-Valve Plus, the company is poised to amass critical experiential data that will facilitate its strategic expansion into international markets. These efforts are anticipated to not only optimize the treatment landscape for patients but also elevate the company's standing within the medical device sector worldwide. This approval stands as a testament to the company's innovative prowess and dedication to improving cardiac care on a global scale.

In summary, the approval of the LuX-Valve Plus within the Hong Kong-Macao Medicine and Equipment Connect not only signifies a critical step forward for Jenscare but also represents a beacon of hope for patients needing effective treatment options for severe tricuspid regurgitation. With the collaboration between Hong Kong, Macao, and the Greater Bay Area, an integrated approach to healthcare is being cultivated, thereby setting the stage for improved medical device accessibility in this dynamic region of Asia.